Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 8/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.40 |
| ▸ | FDPS | P14324 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1109851 | 1.00 | CHRM3 (0.40) | CHRM3CHRM2CHRM4CHRM1FDPS | |
| SCHEMBL1110599 | 1.00 | CHRM3 (0.40) | CHRM3CHRM2CHRM4CHRM1FDPS | |
| SCHEMBL12855714 | 0.89 | CHRM3 (0.41) | CHRM3CHRM2CHRM4CHRM1FDPS | |
| SCHEMBL13093510 | 0.88 | CHRM3 (0.39) | CHRM3CHRM2CHRM4CHRM1POLB | |
| SCHEMBL1109808 | 0.87 | CHRM3 (0.38) | CHRM3CHRM2CHRM4CHRM1POLB | |
| SCHEMBL14290902 | 0.86 | ALDH1A1 (0.37) | CHRM3CHRM2CHRM4CHRM1POLB | |
| SCHEMBL12855710 | 0.85 | CHRM3 (0.36) | CHRM3CHRM2CHRM4CHRM1POLB | |
| SCHEMBL1109817 | 0.84 | CHRM3 (0.36) | CHRM3CHRM2CHRM4CHRM1POLB | |
| SCHEMBL1109790 | 0.83 | CHRM3 (0.41) | CHRM3CHRM2CHRM4CHRM1POLB | |
| SCHEMBL1109782 | 0.83 | CHRM3 (0.41) | CHRM3CHRM2CHRM4CHRM1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-11-01 | — | — | US | disclosed |
| EP-2280006-A1 | PHARMACEUTICAL COMPOSITION FOR INHALATION COMPRISING AN OXAZOLE OR THIAZOLE M3 MUSCARINIC RECEPTOR ANTAGONIST | Pulmagen Therapeutics (Synergy) Limited (GB) | 2011-02-02 | — | — | EP | disclosed |
| EP-1924570-B1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS SYNERGY (GB) | 2010-10-20 | — | — | EP | disclosed |
| US-20100113540-A1 | Azole and Thiazole Derivatives and Their Use | ARGENTA DISCOVERY LIMITED (GB) | 2010-05-06 | — | — | US | disclosed |
| US-20100113540-A1 | Azole and Thiazole Derivatives and Their Use | ARGENTA DISCOVERY LIMITED (GB) | 2010-05-06 | — | — | US | disclosed |
| US-20100113540-A1 | Azole and Thiazole Derivatives and Their Use | ARGENTA DISCOVERY LIMITED (GB) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113540-A1 | Azole and Thiazole Derivatives and Their Use | CHRM3, CHRM2, CHRM1 | CHRM3 1/4885CHRM2 2/4885CHRM4 11/4885 |
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | CHRM3, GPR65, GPR34 | CHRM3 1/4885CHRM2 12/4885CHRM4 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.